Exiqon to Divest US-based CLIA Lab to Consolidate Dx Business in Denmark

As a consequence of the divestiture, Exiqon said it would seek partners to co-develop and commercialize its miRNA-based diagnostic products. The company has ongoing diagnostic development programs for colon cancer recurrence, identification of cancer of unknown primary, and early detection of colon cancer in serum.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.